We’re committed to transparency and cost-effective investing and helping you achieve your goals. Whether you’re a conservative investor looking for consistent returns or a growth seeker, we provide diversified exposure to a professionally managed portfolio of equities and alternatives. Source :EXponent.com

A+ Investor is a stock screening tool that grades stocks on key investment factors, including Value, Momentum, Quality and Estimate Revisions. Its proprietary algorithms calculate scores for each factor and generate a single rating for each stock. Click into any ticker to see its A+ Investor grade.

How to Assess Risk Tolerance in Your Investments

Exponent, a British private equity firm, is believed to be close to spending EUR1 billion on its latest Irish “platform” acquisition, Kingsbridge Healthcare Group, Northern Ireland’s largest hospital group. Its previous purchases in Ireland include the EUR300 million purchase of Michael Burke’s Chanelle Pharma, a Galway-based veterinary drugmaker, and the €160 million buyout of Xeinadin, an acquisitive professional services firm with operations in Dublin, which was led by Derry Crowley.

The company was set up in 2004 by four former senior directors of 3i, and specializes in backing family or founder-owned businesses and “corporate carve-outs”. Its first deal was a carve-out: the Times Education Supplement, which it acquired from News Corp for PS300m. It later bought online rail ticket seller Trainline from Virgin and is currently reshaping Xeinadin through a series of bolt-on acquisitions.

Debevoise & Plimpton is advising the private equity firm on its latest fund, Exponent Private Equity Partners III, LP, which reached its final close at over PS1 billion in January, exceeding its target of PS800 million. The team advising Exponent is led by London-based partner Geoffrey Kittredge, supported by associates John Rife and Alex Howard.